SYDNEY, April 25, 2026, 08:02 AEST
Cochlear Limited finished Friday at A$97.35, just off its lowest point of the week. The hearing-implant maker’s profit warning had already erased more than 40% from the share price over three sessions. Shares gained 2.47% in Friday’s trade but sat well beneath Tuesday’s A$167.94 finish.
It’s moved beyond a single soft quarter. Investors are now pushing Cochlear to prove its adult-and-senior implant franchise can still deliver the kind of resilient growth it’s known for, the sort that’s supposed to withstand downturns. Instead, the business is looking more like a cyclical play — vulnerable to swings in consumer sentiment, referral pipelines, and hospital resources. Morningstar’s Shane Ponraj slashed his fair value estimate by more than half, to A$110, flagging what he called more deep-rooted structural challenges.
The Australian share market takes a pause Saturday for Anzac Day. ASX Trade confirmed that cash market activity—including trading, clearing, and settlement—resumes on Monday, so market direction will have to wait until after New South Wales’ long weekend.
Cochlear slashed its FY26 underlying NPAT outlook to between A$290 million and A$330 million, down from an earlier range of A$435 million to A$460 million. The company is now guiding for second-half sales growth of just 2% to 6% in constant currency, which factors out currency moves.
The company reported that developed-market implant revenue held steady in the third quarter when measured at constant currency. Management pointed to sluggish U.S. consumer sentiment, a drop in referrals via the hearing-aid channel, capacity constraints in both the UK and Germany, plus industrial action impacting Italy and Spain.
Trouble in the Middle East is weighing, too. Cochlear flagged possible cancellations and shipping hold-ups due to the conflict, warning it might need to set aside as much as A$10 million for receivables—unpaid customer invoices. The company also cited about A$20 million lost on weaker factory-cost recovery, A$18 million to A$25 million in restructuring costs, and a further A$25 million after-tax foreign exchange loss.
Chief Executive Dig Howitt described hearing loss in adults and seniors as “a discretionary intervention,” emphasizing that Cochlear must continue efforts to “medicalise hearing loss.” Howitt maintained confidence in the company’s market standing, with strong uptake of the Nucleus Nexa System noted.
Cochlear shares tumbled 40.7% on Wednesday, ending the day at A$99.58—the stock’s lowest finish since March 2016, according to Reuters. The company’s revised profit guidance landed well below expectations, with the midpoint missing the Visible Alpha consensus of A$402.5 million by a considerable margin.
Selling pressure continued. Cochlear shares finished Thursday at A$95.00, down 4.6%, after dipping as low as A$91.33 earlier, ABC News reported. Friday saw a slight bounce.
Then came the broker downgrades. Citi lowered Cochlear to Sell, slashing its target price to A$95 from A$210. UBS shifted to Neutral from Buy, its target down to A$109 from A$302. Over at Morgan Stanley, the team upgraded to Equal-weight from Underweight but still trimmed the price target to A$119, down from A$194.
Derek Jellinek, healthcare analyst at Morgans, flagged “near-term earnings visibility has deteriorated materially,” adding that demand now looks “more cyclical than previously assumed,” according to Stockhead. Morgans maintained its Hold call, but slashed the 12-month target price to A$107.17, down from A$214.93. Stockhead
The warning rattled hearing-health stocks in Europe. Shares of Demant, Sonova, and Amplifon slipped after Cochlear’s update, according to MarketScreener, as investors took the U.S. consumer sentiment signal as a red flag for any company with significant North American exposure.
The risk isn’t one-sided. If U.S. referrals bounce back sooner, or European surgery schedules open up, or deliveries in the Middle East pick up speed, the company might be able to stick to its new forecast. On the flip, if adults and seniors choose to put off implant procedures for good, expect the company to spend more on driving referrals and building the market, with softer volumes squeezing margins further.
There were a few bright spots in the update. Services revenue jumped 13% for the third quarter on a constant currency basis; acoustics revenue climbed 11%. Still, what matters most to investors comes down to the core issue—when will the implant segment regain momentum, and how much will it take to get there?
